Genomic profiling of relapsed small cell lung cancer reveals potential pathways of therapeutic targets.

ABSTRACT:

Background

Almost all patients with small cell lung cancer (SCLC) relapse. The therapeutic options of relapsed SCLC are limited, and the clinical outcomes are poor. Thus, genomic profiling of relapsed SCLC patients may help to develop more effective therapeutic options.

Methods

We collected blood specimens and follow-up information from a consecutive cohort of 31 patients diagnosed with relapsed SCLC in Zhongnan Hospital, Wuhan University, between 2018 and 2019, to analyze the comprehensive genomic profiling, and to investigate the impact of genomic alterations on therapeutic options and survival.

Results

In our cohort of relapsed SCLC, the median number of genomic alterations was 5 (range, 1-11) per sample. The majority of patients were defined as low tumor mutation

SUBMITTER: Ouyang W 

PROVIDER: S-EPMC10797366 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature